Best of ASCO - 2014 Annual Meeting

 

Welcome

Circulating Biomarkers

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Addition of immunotherapy in adjuvant setting could be a promising avenue of colorectal cancer (CRC) treatment, especially in patients with higher levels of programmed cell death ligand-1 (PD-L1) positive circulating epithelial tumor cells (CETC) after neoadjuvant chemotherapy.

Monika Pizon

e14036

Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.

Nicholas Willumsen

e14050

Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.

Kyle Gregory Mitchell

e14047

Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).

Marco Adelmo James Iafolla

2542

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients?

Daniele Fanale

e14035

CD4+ T-cell immunity predicts long-lasting antitumor immunity after PD-1 blockade therapy.

Kyoichi Kaira

2545

Characteristics of POLE and POLD1 gene variations in Chinese cancer patients.

Jianfei Yao

e14031

Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.

Laura Kennedy

e14032

Clinical implication of monitoring PD-L1+ circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy.

Andrew Daniel Hoffmann

e14044

Clonal expansion of tumor infiltrating lymphocytes (TILs) in the peripheral blood of metastatic melanoma patients is significantly associated with response to CTLA4 blockade-based immunotherapy.

Arjun Khunger

2541

Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.

Chad Garner

e14027

Correlation between peripheral CD8+PD-1+ T cells diversity, tumor mutation burden (TMB) and T cell clones with anti-PD-1 antibody treatment of lung cancer patients: TCR repertoire as a novel predictive biomarker.

Seiji Matsumoto

e14041

Correlation of HERVK with efficacy on anti-PD-1/PD-L1 therapy in a pilot metagenomics study on Chinese advanced lung cancer patients.

Haitao Tao

e14046

ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.

Everett J Moding

2547

Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC).

Rui Wang

2544

Effect of radiotherapy on the residual circulating epithelial tumor cells (CETCs) and their programmed cell death ligand 1 (PD-L1) status in breast cancer patients.

Dorothea Schott

e14034

Evolution of the myeloid-derived suppressor cells in advanced breast cancer and comparative analysis with a healthy population cohort.

Natalia Palazón-Carrión

2543

Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.

Jin-Sung Chung

e14038

Immunological and clinical profiles of patients with advanced or metastatic melanoma receiving immune checkpoint inhibitors to investigate potential biomarkers for immune-related adverse events.

Stephanie A. Berg

e14037

Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.

Marzia Del Re

e14054

Molecular circulating tumor DNA response to identify long-term survival in patients receiving immunotherapy with initial radiologic stable disease.

Matthew David Hellmann

2546

PD-L1 expression on circulating tumor cells and prognosis of breast cancer patients.

Xuefei Wang

e14028

Plasma biomarkers to predict pembrolizumab response in HCC patients.

Lynn G. Feun

e14043

Prognostic interaction of smoking history with circulating regulatory T cells in advanced non-small cell lung cancer.

Chao Liu

e14030

Quantification of activated and exhausted immune cell populations and simultaneous characterization of circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.

Gordon Vansant

e14033

Real-time monitoring of circulating stromal cells in the blood to predict responsiveness of new-line therapies in metastatic breast cancer.

Daniel Adams

e14048

Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.

Sofia Agelaki

e14045

TCR repertoire analysis from peripheral blood for prognostic assessment of patients during treatment.

Sadanand Vodala

e14040